CompletedPhase 2NCT00243191
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Studying Dermatofibrosarcoma protuberans
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- Scott Schuetze, MD, PhDUniversity of Michigan
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2009
Study locations (4)
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Pennsylvania Onc/Hem Assoc., Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00243191 on ClinicalTrials.gov